Skip to content

A novel surgical technique for preventing pancreatic leakage after attaching the pancreas to the small intestine

Efficacy of a novel pancreaticojejunostomy technique in preventing pancreatic leakage and hemorrhage after pancreaticoduodenectomy: protocol for a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN59731654
Enrollment
390
Registered
2019-12-06
Start date
2019-12-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periampullary tumors Cancer Malignant neoplasm of pancreas

Interventions

Based on the included eligible patients with highly suspected periampullary tumors, the hospital statisticians will generate a random digital sequence using SAS 9.1 program (SAS Institute Inc., Cary,

Sponsors

Shenjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Periampullary tumors indicated by at least two imaging examinations or pathological biopsy before surgery 2. =18 years of age 3. Provision of written informed consent by patients or their legal guardians

Exclusion criteria

Exclusion criteria: 1. Extensive tumor metastasis 2. Abnormal blood coagulation 3. Renal dysfunction (creatinine >250 µmol/L) 4. Chronic liver disease 5. History of radiation therapy 6. American Society of Anesthesiologists (ASA) class IV-V 7. Life expectancy <48 hours 8. Lactating or pregnant women 9. Participation in other drug clinical trials

Design outcomes

Primary

MeasureTime frame
Incidence of pancreatic fistula within 30 days after surgery (defined as an abdominal drain or incision output of fluid with an amylase level > 3 times the upper limit of institutional normal serum amylase activity for 3 days)

Secondary

MeasureTime frame
1. Incidence of postoperative hemorrhage within 30 days of surgery (defined as bloody drainage fluid, hematemesis, melena, unexplained hypotension or tachycardia, abnormal laboratory tests, and aggravated clinical manifestations) evaluated based on the results of gastrointestinal endoscopy, angiography, perfusion imaging, CT or re-operation 2. Incidence of delayed gastric emptying: 2.1. Grade A delayed gastric emptying: indwelling nasogastric tubes for 4-7 days after surgery or re-indwell nasogastric tubes 3 days after surgery because of nausea and vomiting or being unable to tolerate solid food 7-14 days after surgery 2.2. Grade B delayed gastric emptying: indwelling nasogastric tubes for 8-14 days after surgery or re-indwell nasogastric tubes 7 days after surgery, or being unable to tolerate solid food 14-21 days after surgery 2.3. Grade C delayed gastric emptying: indwelling nasogastric tubes for over 14 days or re-indwell nasogastric tubes 14 days after surgery or being unable to tolerate solid food 21 days after surgery 3. Surgical indicators: Patient’s operation time and intraoperative blood loss 4. Economic indicators: Patients’ average hospital stay and hospitalization cost

Countries

China

Contacts

Public ContactXiaodong Tan
tanxd@sj-hospital.org+86 (0)249661531111

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026